Literature DB >> 28634502

Impact of Neurological Follow-Up on Early Hospital Readmission Rates for Acute Ischemic Stroke.

Alexander Allen1, Todd Barron2, Ashley Mo3, Richard Tangel4, Ruth Linde2, Rodney Grim5, John Mingle6, Ellen Deibert2.   

Abstract

INTRODUCTION: Despite advances in stroke care, readmission rates for patients with ischemic stroke remain high. Although factors such as age, diabetes, and continuous use of antiplatelet agents have been found to predict readmission rates, the impact of after-hospital care has not been examined.
METHODS: The present study reviewed the charts of 416 patients with acute ischemic stroke and recorded stroke-related comorbidities, neurology follow-up within 21 days, readmission at 0 to 30 days, readmission at 31 to 90 days, and any reasons for readmission.
RESULTS: For those readmitted within 0 to 30 days, reasons for readmission were other medical conditions (62.5%), recurrent stroke (30.4%), and elective procedure (7.1%). For those readmitted within 31 to 90 days, reasons for readmission were other medical conditions (62.3%), recurrent stroke (15.1%), and elective procedure (22.6%). There was no significant relationship between being evaluated within 21 days and readmission at 0 to 30 or 31 to 90 days. However, those who did have a neurology follow-up at any point in time had a lower readmission rate of 10.6% compared to those who never came back (19.2%, P = .017). Patients with coronary artery disease and diabetes had a significantly higher likelihood of readmission within 0 to 30 days.
CONCLUSION: The present study suggests that neurology follow-up at any point in time for patients with acute ischemic stroke may reduce short-term readmissions, but special attention to optimizing management of other underlying medical conditions, coronary artery disease, or diabetes may also help reduce overall readmissions. Patients with stroke, therefore, may benefit from a follow-up with both the primary care and neurology in a coordinated fashion to prevent early readmissions at 30 days.

Entities:  

Keywords:  comorbidities; neurology; outcome; stroke

Year:  2017        PMID: 28634502      PMCID: PMC5467821          DOI: 10.1177/1941874416684456

Source DB:  PubMed          Journal:  Neurohospitalist        ISSN: 1941-8744


  16 in total

1.  Readmission within 1 month of discharge among patients with acute ischemic stroke: results of the University HealthSystem Consortium Stroke Benchmarking study.

Authors:  M Fareed K Suri; Adnan I Qureshi
Journal:  J Vasc Interv Neurol       Date:  2013-12

2.  30-Day risk-standardized mortality and readmission rates after ischemic stroke in critical access hospitals.

Authors:  Judith H Lichtman; Erica C Leifheit-Limson; Sara B Jones; Yun Wang; Larry B Goldstein
Journal:  Stroke       Date:  2012-08-30       Impact factor: 7.914

3.  Hospital-level variation in mortality and rehospitalization for medicare beneficiaries with acute ischemic stroke.

Authors:  Gregg C Fonarow; Eric E Smith; Mathew J Reeves; Wenqin Pan; Daiwai Olson; Adrian F Hernandez; Eric D Peterson; Lee H Schwamm
Journal:  Stroke       Date:  2010-12-16       Impact factor: 7.914

4.  Five-year rehospitalization outcomes in a cohort of patients with acute ischemic stroke: Medicare linkage study.

Authors:  Kamakshi Lakshminarayan; Candace Schissel; David C Anderson; Gabriela Vazquez; David R Jacobs; Mustapha Ezzeddine; Russell V Luepker; Beth A Virnig
Journal:  Stroke       Date:  2011-04-07       Impact factor: 7.914

5.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

Review 6.  Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century.

Authors:  Valery L Feigin; Carlene M M Lawes; Derrick A Bennett; Craig S Anderson
Journal:  Lancet Neurol       Date:  2003-01       Impact factor: 44.182

7.  Readmission and death after hospitalization for acute ischemic stroke: 5-year follow-up in the medicare population.

Authors:  Dawn M Bravata; Shih-Yieh Ho; Thomas P Meehan; Lawrence M Brass; John Concato
Journal:  Stroke       Date:  2007-05-17       Impact factor: 7.914

8.  Influence of hospital-level practices on readmission after ischemic stroke.

Authors:  James F Burke; Lesli E Skolarus; Eric E Adelman; Mathew J Reeves; Devin L Brown
Journal:  Neurology       Date:  2014-05-16       Impact factor: 9.910

9.  The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

Authors:  Peter Sandercock; Joanna M Wardlaw; Richard I Lindley; Martin Dennis; Geoff Cohen; Gordon Murray; Karen Innes; Graham Venables; Anna Czlonkowska; Adam Kobayashi; Stefano Ricci; Veronica Murray; Eivind Berge; Karsten Bruins Slot; Graeme J Hankey; Manuel Correia; Andre Peeters; Karl Matz; Phillippe Lyrer; Gord Gubitz; Stephen J Phillips; Antonio Arauz
Journal:  Lancet       Date:  2012-05-23       Impact factor: 79.321

Review 10.  Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis.

Authors:  Joanna M Wardlaw; Veronica Murray; Eivind Berge; Gregory del Zoppo; Peter Sandercock; Richard L Lindley; Geoff Cohen
Journal:  Lancet       Date:  2012-05-23       Impact factor: 79.321

View more
  3 in total

1.  Implementing a Neurohospitalist Program Improves Stroke Care Metrics and Patient Satisfaction Scores.

Authors:  Renée E Pierre-Louis; Kelly Pannikodu; Maher Madhoun; Josette Hartnett; Suzanne Rose
Journal:  Neurohospitalist       Date:  2022-02-11

2.  Frequent Emergency Department Visits After Spontaneous Intracerebral Hemorrhage: Who Is at Risk?

Authors:  Jerina Nogueira; Pedro Abreu; Patrícia Guilherme; Ana Catarina Félix; Fátima Ferreira; Hipólito Nzwalo; Ana Marreiros
Journal:  Neurohospitalist       Date:  2018-02-07

3.  The Impact of Ischaemic Stroke Subtype on 30-day Hospital Readmissions.

Authors:  Anna Therese Bjerkreim; Andrej Netland Khanevski; Henriette Aurora Selvik; Ulrike Waje-Andreassen; Lars Thomassen; Halvor Naess; Nicola Logallo
Journal:  Stroke Res Treat       Date:  2018-12-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.